Revelation Biosciences Inc Cash Flow-to-Debt Ratio
Revelation Biosciences Inc cash flow-to-debt ratio. Revelation Biosciences Inc (REVB) has a Cash Flow-to-Debt Ratio of -1.05x as of June 2026, meaning its operating cash flow of $-2.56 Million could theoretically repay -1% of its total liabilities ($2.43 Million) in one year. Check Revelation Biosciences Inc earnings quality ratio to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Revelation Biosciences Inc (2016–2025)
Cash flow-to-debt ratio of Revelation Biosciences Inc from 2016 to 2025. Historical debt coverage capacity for Revelation Biosciences Inc across 10 annual periods. Check REVB capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
Revelation Biosciences Inc Cash Flow-to-Debt Ratio by Year (2016–2025)
Revelation Biosciences Inc cash flow-to-debt ratio by year from 2016 to 2025. Year-by-year debt coverage analysis for Revelation Biosciences Inc. For the full cash flow conversion analysis, see Revelation Biosciences Inc (REVB) cash flow conversion.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -3.04x | $-8.27 Million | $2.72 Million | ▲ +68.3% |
| 2024 | -9.57x | $-18.32 Million | $1.91 Million | ▼ -631.2% |
| 2023 | -1.31x | $-7.29 Million | $5.56 Million | ▲ +48.1% |
| 2022 | -2.52x | $-11.22 Million | $4.45 Million | ▲ +51.3% |
| 2021 | -5.18x | $-11.09 Million | $2.14 Million | ▼ -15176.9% |
| 2020 | -0.03x | $-215.07K | $6.34 Million | ▼ -100.0% |
| 2019 | 1561.67x | $41.09 Million | $26.31K | ▲ +10499175.7% |
| 2018 | 0.01x | $32.58 Million | $2.19 Billion | ▲ +17.2% |
| 2017 | 0.01x | $24.25 Million | $1.91 Billion | ▲ +88.8% |
| 2016 | 0.01x | $11.60 Million | $1.73 Billion | — |